Is Madrigal Pharmaceuticals Inc (MDGL) overvalued? · rev $180.1M
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ.
This page asks whether Madrigal Pharmaceuticals Inc (MDGL) looks expensive on cached numbers — not a short thesis.
Latest reported MDGL revenue for 2024-12-31 was $180.1M. Net income was -$465.9M. MDGL currently screens at market cap $11.56B.
MDGL currently screens at market cap $11.56B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MDGL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MDGL stock page for the full model, not this heading.
Not investment advice.